What was the primary driver of Amgen's revenue growth in Q1 2003?

The primary driver of Amgen's revenue growth in the first quarter of 2003 was a significant increase in product sales, which rose by 80% to $1.64 billion. This surge was largely fueled by the strong performance of key products, particularly Enbrel®, Neulasta™, and Aranesp®.

How did the acquisition of Immunex impact the financial results?

The acquisition of Immunex, completed in July 2002, had its results fully integrated into Amgen's Q1 2003 financial statements. While contributing to the substantial increase in total revenues and product sales, the acquisition also led to higher operating expenses, including amortization of acquired intangible assets, research and development, and selling, general, and administrative costs, as the company focused on integration and growth.

What is the company's outlook regarding liquidity and capital resources?

Amgen's liquidity and capital resources appear strong. Cash provided by operating activities significantly increased year-over-year to $780.8 million. The company also reported substantial cash, cash equivalents, and marketable securities totaling $4.76 billion. Amgen anticipates capital expenditures of $1.3 billion to $1.5 billion for 2003 to support manufacturing expansions and research facilities, and believes existing funds and financing sources are adequate for its foreseeable needs.

How are Amgen's key products performing individually?

Combined EPOGEN® and Aranesp® sales increased by 45% to $801.9 million, with Aranesp® sales showing robust growth driven by new indications. NEUPOGEN® sales saw a 20% decrease to $284.0 million, largely due to the conversion of patients to the newer Neulasta™, which had combined sales of $257.9 million. ENBREL® sales contributed significantly, reaching $274.0 million, with supply increasing to meet demand.

AMGN 10-Q Quarterly Report Q1 FY2003 — Revenue, Net Income, EPS

Summary

Amgen Inc. reported strong performance for the first quarter of 2003, with net income increasing by approximately 45% year-over-year to $493.3 million, or $0.37 per diluted share. This growth was significantly driven by a 80% surge in product sales, reaching $1.64 billion, largely attributable to the substantial contributions of Enbrel®, Neulasta™, and Aranesp®. The company's strategic acquisition of Immunex in July 2002 continues to be integrated, with its results fully included in the current period's financials. This acquisition, along with robust organic growth from key products, underscores Amgen's expanding market presence and its commitment to advancing its product pipeline. Investors should note the significant increase in operating expenses, including R&D and SG&A, which reflect investments in growth and integration efforts.

Key Highlights

1Net income increased by 45% to $493.3 million ($0.37 per diluted share) compared to $340.9 million ($0.32 per diluted share) in the prior year period.
2Total revenues grew by 75% to $1,761.2 million from $1,008.5 million in Q1 2002.
3Product sales surged by 80% to $1,635.9 million, driven by strong performance in Enbrel®, Neulasta™, and Aranesp®.
4Operating income increased by 45% to $662.2 million.
5The acquisition of Immunex is now fully reflected in the financial statements, contributing to increased revenues and expenses.
6Cash provided by operating activities increased significantly to $780.8 million from $486.9 million in the prior year.
7Amgen repurchased $450.6 million of its common stock during the quarter, as part of its ongoing stock repurchase program.

AMGEN INC Quarterly Report for Q1 Ended Mar 31, 2003

Summary

Key Highlights

Frequently Asked Questions